Literature DB >> 20974028

Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT.

Daniel Canter1, Richard E Greenberg, Eric M Horwitz, Alexander Kutikov, Jinsheng Li, Christopher Long, Mark Buyyounouski, Stephen A Boorjian.   

Abstract

INTRODUCTION: Radiation therapy (RT) after radical prostatectomy (RP) has been associated with a survival benefit in both the adjuvant and salvage setting. Nevertheless, optimal targeting of the prostate bed following surgery remains challenging. The Calypso 4D Localization System (Calypso Medical Technologies, Seattle, WA, USA) is a target positioning device that continuously monitors the location of three implantable electromagnetic transponders. We describe our technique of ultrasound-guided placement of these transponders into the prostate bed for adjuvant and salvage RT.
METHODS: Seventeen patients presenting to Fox Chase Cancer Center for postoperative RT underwent transrectal ultrasound-guided placement of Calypso beacons. The three transponders were placed approximately 1 cm apart in a triangular fashion around the vesico-urethral anastomosis and in the retrovesicular tissue.
RESULTS: All patients were successfully implanted without periprocedural complications. Appropriate beacon position was confirmed by CT scan performed at the time of RT simulation. Intensity-modulated radiation therapy was delivered at a dose of 68 Gy (range 64-68). Treatment was well-tolerated with no Grade 3 or 4 toxicities. Grade > 2 enteritis was not observed, and there were no cases of rectal bleeding. Genitourinary toxicity was noted in 10 patients and consisted of Grade 1 and 2 frequency and dysuria. No patient developed gross hematuria or urinary retention. All patients (9/9) with at least 6 months of follow up after treatment had an undetectable PSA.
CONCLUSIONS: The placement of Calypso transponders for adjuvant/salvage RT is a safe and efficacious method for treatment targeting with an acceptable acute toxicity profile.

Entities:  

Mesh:

Year:  2010        PMID: 20974028

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  6 in total

1.  Prostate bed target interfractional motion using RTOG consensus definitions and daily CT on rails : Does target motion differ between superior and inferior portions of the clinical target volume?

Authors:  Vivek Verma; Shifeng Chen; Sumin Zhou; Charles A Enke; Andrew O Wahl
Journal:  Strahlenther Onkol       Date:  2016-12-01       Impact factor: 3.621

2.  Prostate bed motion during intensity-modulated radiotherapy treatment.

Authors:  Tracy Klayton; Robert Price; Mark K Buyyounouski; Mark Sobczak; Richard Greenberg; Jinsheng Li; Lanea Keller; Dennis Sopka; Alexander Kutikov; Eric M Horwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

Review 3.  Smart Radiation Therapy Biomaterials.

Authors:  Wilfred Ngwa; Francis Boateng; Rajiv Kumar; Darrell J Irvine; Silvia Formenti; Twalib Ngoma; Carsten Herskind; Marlon R Veldwijk; Georg Lars Hildenbrand; Michael Hausmann; Frederik Wenz; Juergen Hesser
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-01       Impact factor: 7.038

4.  Using fiducial markers in the prostate bed in postprostatectomy external beam radiation therapy improves accuracy over surgical clips.

Authors:  I Fortin; J-F Carrier; M-C Beauchemin; D Béliveau-Nadeau; G Delouya; D Taussky
Journal:  Strahlenther Onkol       Date:  2014-02-21       Impact factor: 3.621

5.  Intrafractional prostate motion during external beam radiotherapy monitored by a real-time target localization system.

Authors:  Xu Tong; Xiaoming Chen; Jinsheng Li; Qianqian Xu; Mu-Han Lin; Lili Chen; Robert A Price; Chang-Ming Ma
Journal:  J Appl Clin Med Phys       Date:  2015-03-08       Impact factor: 2.102

6.  68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial.

Authors:  Patrick Bowden; Andrew W See; Kevin So; Nathan Lawrentschuk; Daniel Moon; Declan G Murphy; Ranjit Rao; Alan Crosthwaite; Dennis King; Hodo Haxhimolla; Jeremy Grummet; Paul Ruljancich; Dennis Gyomber; Adam Landau; Nicholas Campbell; Mark Frydenberg; Lloyd M L Smyth; Skye Nolan; Stella M Gwini; Dean P McKenzie
Journal:  World J Urol       Date:  2021-06-02       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.